FDA Releases Draft Guidance On Closed-Loop Artificial Pancreas Devices

Draft issued Dec. 1 emphasizes flexible clinical trial designs to support approval of glucose monitor/insulin pump combination devices that work together without the need for patient intervention.

FDA released long-awaited draft guidance Dec. 1 to help pave the way for the development of a fully closed-loop “artificial pancreas” device, which is poised to change the way patients manage type 1 diabetes by automating the process.

The draft outlines what information sponsors should include in investigational device exemption applications needed to begin U.S. clinical trials and...

More from Clinical Trials

More from R&D